ArticleAnnals of surgical oncology2025
Israel's First Port-Based Hepatic Artery Infusion Program: Early Outcomes in Colorectal Liver Metastases.
Article in Annals of surgical oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundOver the last three decades, hepatic arterial infusion (HAI) chemotherapy combined with systemic therapy has been established as a treatment strategy for patients with unresectable liver metastases. Facilitating a HAI program outside the USA and Europe remains underutilized in regions, including Israel, and requires multidisciplinary collaboration. The purpose of this study is to describe the feasibility and early outcomes of the initiation of the first hepatic artery infusion program in Israel. PATIENTS AND
methodsThis retrospective analysis was conducted at a tertiary medical center in Israel. It included 21 patients with unresectable colorectal liver metastases who underwent hepatic artery infusion port placement between February 2020 and March 2022. All participants underwent hepatic artery infusion port placement with most subsequently receiving chemotherapy. The study evaluated perioperative outcomes, complication rates, response rates, and conversion to resectability at 6 months.
resultsHepatic arterial infusion chemotherapy was successfully administered to 95% of patients. The overall 90-day major complication rate was 24%, with no reported mortality. At 6 months, the partial response rate was 33%, and the disease control rate was 83%. Four out of five patients (80%) with neoadjuvant intent converted from unresectable to resectable during HAI treatment.
conclusionsThis study demonstrates the feasibility and safety of implementing a new HAI program for carefully selected patients with colorectal liver metastases. Despite the cohort being heavily pretreated with systemic chemotherapy, promising hepatic response rates and disease control rates were observed. These findings support the potential for expanding access to HAI therapy in new geographic regions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.